Moderna : Company in negotiations for new orders for fall of 2023 in U.S., Japan, and E.U., in addition to reiterating 2023 minimum sales expectations of approximately $5.0 billion from previously announced COVID-19 vaccine Advanced Purchase Agreements - Form 8-K
Company in negotiations for new orders for fall of 2023 in U.S., Japan, and E.U., in addition to reiterating 2023 minimum sales expectations of approximately $5.0 billion from previously... | May 4, 2023